Profil
Samuel Henderson is currently the Chief Scientific Officer at Cerecin, Inc. Previously, he worked as a Principal at The University of Colorado and as a Lead Scientist at Genoplex, Inc. He completed his undergraduate degree at the University of Washington and obtained his doctorate from the University of Chicago.
Aktiva positioner av Samuel Henderson
| Företag | Position | Start |
|---|---|---|
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat central nervous system disorders | Teknisk/Vetenskaplig/F&U Direktör | - |
Tidigare kända positioner av Samuel Henderson
| Företag | Position | Slut |
|---|---|---|
Genoplex, Inc.
Genoplex, Inc. Packaged SoftwareTechnology Services Develops AI-powered technology platform to simplify the logistics of patient referrals for advanced therapies | Teknisk/Vetenskaplig/F&U Direktör | - |
The University of Colorado
The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
Samuel Hendersons utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 5 |
|---|---|
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Develops therapies to treat central nervous system disorders | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Colorado
The University of Colorado Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genoplex, Inc.
Genoplex, Inc. Packaged SoftwareTechnology Services Develops AI-powered technology platform to simplify the logistics of patient referrals for advanced therapies | Technology Services |
















